Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 8/20 | 0.51 |
| ▸ | GRB7 | Q14451 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | AGPAT2 | O15120 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20559203 | 0.90 | IDH1 (0.49) | IDH1GRB7HPGDKDRCYP1A2 | |
| SCHEMBL17603457 | 0.90 | IDH1 (0.49) | IDH1GRB7HPGDCYP1A2CYP2C19 | |
| SCHEMBL20559199 | 0.90 | IDH1 (0.49) | IDH1GRB7HPGDKDRCYP1A2 | |
| SCHEMBL17603944 | 0.86 | IDH1 (0.55) | IDH1 | |
| SCHEMBL19991436 | 0.86 | IDH1 (0.55) | IDH1 | |
| SCHEMBL17603504 | 0.82 | IDH1 (0.65) | IDH1 | |
| SCHEMBL17601390 | 0.80 | IDH1 (0.73) | IDH1 | |
| SCHEMBL21112073 | 0.76 | IDH1 (0.47) | IDH1CYP1A2CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL17603415 | 0.76 | IDH1 (0.47) | IDH1CYP1A2CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL17603435 | 0.76 | IDH1 (0.57) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194375-B1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2018-11-21 | — | — | EP | claimed |
| US-10005734-B2 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | claimed |
| EP-3194375-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2017-07-26 | — | — | EP | claimed |
| US-20160083349-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | claimed |
| WO-2016044782-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | claimed |
| US-20190210970-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-10266495-B2 | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-3194375-B1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180327361-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-10005734-B2 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3194375-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20160083349-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2016044782-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005734-B2 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | IDH3A, IDH1, IDH2 | IDH1 2/4885GRB7 1027/4885HPGD 175/4885 |
| US-10266495-B2 | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | IDH3A, IDH1, IDH3B | IDH1 2/4885GRB7 1243/4885HPGD 276/4885 |
| US-20190210970-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH2, IDH3A | IDH1 1/4885GRB7 3058/4885HPGD 45/4885 |
| US-20160083349-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH3A, IDH1, IDH2 | IDH1 2/4885GRB7 1027/4885HPGD 175/4885 |
| US-20180327361-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH3A, IDH1, IDH3B | IDH1 2/4885GRB7 1243/4885HPGD 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.